Evidence map›Paper›PMID 33872216›Full record

ArticleAging2021

Expression and prognosis analyses of BUB1, BUB1B and BUB3 in human sarcoma.

Zeling Long, Tong Wu, Qunyan Tian, Luke A Carlson, Wanchun Wang, Gen Wu

Open access · greenAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. BUB1B is a novel prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Expression and clinical significance of BUB1 in esophageal cancer.American journal of translational research · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Zeling LongDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Tong WuDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qunyan TianDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Luke A CarlsonUniversity of Pittsburgh, Pittsburgh, PA 15260, USA.
Wanchun WangDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Gen WuDepartment of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CNUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Budding Uninhibited By Benzimidazoles are a group of genes encoding proteins that play central roles in spindle checkpoint during mitosis. Improper mitosis may lead to aneuploidy which is found in many types of tumors. As a key mediator in mitosis, the dysregulated expression of BUBs has been proven to be highly associated with various malignancies, such as leukemia, gastric cancer, breast cancer, and liver cancer. However, bioinformatic analysis has not been applied to explore the role of the BUBs in sarcomas. Herein, we investigate the transcriptional and survival data of BUBs in patients with sarcomas using Oncomine, Gene Expression Profiling Interactive Analysis, Cancer Cell Line Encyclopedia, Kaplan-Meier Plotter, LinkedOmics, and the Database for Annotation, Visualization and Integrated Discovery. We found that the expression levels of BUB1, BUB1B and BUB3 were higher in sarcoma samples and cell lines than in normal controls. Survival analysis revealed that the higher expression levels of BUB1, BUB1B and BUB3 were associated with lower overall and disease-free survival in patients with sarcomas. This study implies that BUB1, BUB1B and BUB3 are potential treatment targets for patients with sarcomas and are new biomarkers for the prognosis of sarcomas.

Indexed as

Cell Cycle ProteinsGene Expression Regulation, NeoplasticHumansMitosisPoly-ADP-Ribose Binding ProteinsPrognosisProtein Serine-Threonine KinasesSarcomaStomach NeoplasmsBUB1B protein, humanBUB1 protein, humanBUB3 protein, humanCell Cycle ProteinsPoly-ADP-Ribose Binding ProteinsProtein Serine-Threonine Kinasesbudding uninhibited by benzimidazolesoncogenesarcoma

Identifiers

PMID33872216
PMCPMC8148488
OpenAlexW3155634517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.